Introduction
Stroke is the fifth leading cause of death and a major cause of disability in the United States 1 . Ischemic stroke represents an overwhelming majority of these cases (~87%), occurring when there is localized disruption in blood flow to the brain (e.g., by a blood clot or fatty deposit). Oxygen and nutrient supplies to the affected areas are subsequently reduced and a complex pathologic cascade is initiated resulting in neuronal death within the stroke core (infarct) in addition to the surrounding areas. Neuroinflammation is a crucial component in the pathway leading to this damage, with both resident brain immune cells (microglia) and infiltrating peripheral immune cells (neutrophils, T cells, B cells, and monocytes/macrophages) thought to contribute to this destructive cascade 2, 3 . Activated microglia and macrophages are central to this neuroinflammatory response, with reports of both deleterious and beneficial effects following ischemic stroke 2 . Thus, it is imperative to assess the in vivo contribution of these cells following stroke.
PET is a powerful 3-dimensional molecular imaging technique that enables visualization of biological processes in vivo through the use of specific molecules labeled with positron (β+) emitting radionuclides such as 11 C, 13 N, 15 O and 18 F. This non-invasive method has many advantages over ex vivo methods (e.g., immunohistochemistry) as it permits the acquisition of molecular information in real time, in living intact subjects, and allows for longitudinal investigation. PET imaging of TSPO, a marker of activated microglia and peripheral myeloid-lineage cells, provides a means to quantify and track innate immune cell responses within the body, and can be utilized to assess inflammation after stroke and response to therapeutic interventions. TSPO, formerly known as the peripheral-type benzodiazepine receptor, is an 18 kDa protein that is believed to play a role in cholesterol transport and the synthesis of neurosteroids 4 . Moreover, evidence suggests that TSPO is involved in neuroinflammation and neuronal survival 5, 6 , with reports of increased expression in many neurological disorders involving inflammation including stroke 7 , dementia 8 , Parkinson's disease 9 and multiple sclerosis 10 . TSPO is located on outer mitochondrial membranes and is highly expressed in the periphery, particularly in steroid associated tissues (e.g., glands) and with intermediate levels seen in the heart, kidneys, and lungs 10 .However in the healthy brain, TSPO levels are low and restricted mainly to glia 6, 11 . Upon neuronal injury, such as that observed in stroke, TSPO levels in the central nervous system (CNS) increase significantly. This observed upregulation of TSPO can be exploited to image neuroinflammation in vivo, with expression levels providing an accurate indicator of inflammation severity. Hence, the goal of this method is to accurately quantify thein vivo contribution of neuroinflammation in a mouse model of ischemic stroke using TSPO-PET.
Multiple TSPO tracers have been developed for PET imaging of neuroinflammation. Here, TSPO-PET imaging is described using [
Animal Preparation and Cannulation
1. Weigh mice to determine the maximum volume allowed to be injected into each mouse (i.e., volume of tracer and any saline administered must not exceed 10% of body weight). 2. Anesthetize mice in an induction chamber using 3% Isoflurane and maintain at 1-2% (2 L/min 100% O 2 ). 3. Apply eye lubricant to each mouse and confirm anesthetization via pedal reflex (toe pinch). Adjust anesthesia levels if necessary. 4. Place the mouse onto a heated bed fitted with a nose cone to deliver isoflurane at 1-2% (2 L/min 100% O 2 ). 5. While the mouse is anesthetized, perform tail vein cannulation using the following protocol:
1. Place mouse on its side to expose one of the lateral veins, while head remains in the nose cone. 2. Warm the tail using a heat lamp, being careful not to overheat or burn the tail, and swab with an alcohol wipe to dilate the vein and sterilize the injection site. 3. Hold the needle with the bevel up and align it with the vein at an acute angle. 4. Lightly apply pressure to puncture the skin and level out the needle so it is in line with the vein. 5. Gently push forward a few millimeters past the bevel so the needle enters the vein. 6. Confirm the catheter is in by administering a small (10-20 µL) flush of saline. The saline should leave the syringe smoothly and the vein should clear. If any resistance or back pressure is observed, it is likely the catheter is not in the vein and re-attempting cannulation is advisable. If clotting is observed, use heparin (1,000 units heparin per mL saline) for cannulation setup and flushing. NOTE: We have assessed cannulation with and without heparin in the mouse strain of interest, and since no clotting was observed, saline alone was used for cannulations. 7. Secure the catheter to the tail using a small drop of tissue glue, followed by surgical tape, to ensure that the catheter remains immobile when transferring the mice to the scanner. 8. Remove the flush syringe from the end of catheter and seal the end with lighter, ensuring the researcher is not near any isoflurane or ethanol. 9. Repeat for 3 additional mice so that all 4 mice to be scanned are cannulated and prepared.
6. Turn on the anesthesia flow (2.5% Isoflurane, 2 L/minute 100% O 2 ) connected to the PET/CT and carefully position the mice prone in the scanner bed, ensuring catheters remain in place and each mouse's head is straight and secure within the nose cone. Tape the head and the body of each mouse to the bed with soft surgical tape, ensuring breathing is not restricted by the placement of the tape. Record the position of each mouse to allow for correct location and group allocation for image analysis. 7. Keep mice heated throughout the procedure (e.g., using a heat lamp or hot air pump system to ensure mice are kept warm without overheating). Monitor respiratory rate of all mice, either visually if using an open gantry or through a remote monitoring system using respiratory pads, and alter the anesthesia levels as necessary.
CT Acquisition
1. Once animals are secure in the bed and respiration is stable, turn on the laser cross hairs and move the scanning bed so that they align with the brain of all four mice. Move the scanner bed in to the acquisition position (position 3) with the brains of the mice as close to the center of the FOV as possible. 2. Acquire a scout view image of the mice to verify their position (use a 200 mm FOV), and adjust the position by dragging the FOV box on the interface if necessary. Click "Start Workflow" in the scanner software to begin the CT scan, making sure to select "display interactive user prompts" so the PET scan can be manually started prior to tracer injection.
PET Acquisition
1. Once the mice automatically advance from CT to PET, set up the back of the scanner for [
11 C]DPA-713 injection ( Figure 1C ). Place protective absorbent padding on a ledge and make sure scissors and lighter are on hand. 2. Snip the sealed catheter tubing with scissors, check catheter lines are clear of any bubbles, and confirm the cannula is still within the vein by performing a 10-20 µL saline flush. Load the measured dose syringes from step 6.4 into each of the 4 catheters, keeping track of which dose was given to each mouse. 3. Click "OK" when the PET scan is ready to start while simultaneously starting a 10 second timer. Have two researchers at the back of the scanner with the dose syringes in hand, to inject all 4 mice simultaneously upon the timer reaching zero. Flush each catheter with 50-100 µL of saline (depending on the length of catheter tubing -i.e., the dead volume) to make sure the full dose enters the tail vein, and re-seal the tubing once again using a lighter. 4. Measure the dose syringes using a dose calibrator to obtain a residual radioactivity value (any tracer left in the syringe). Take note of the values and the time they are recorded. 5. Once the scan is complete, home the PET bed to the original position using the horizontal "home" button within the motion control panel.
Remove the mice from the scanner and carefully remove the catheter. Gently apply pressure to the cannulation site to prevent excessive bleeding. 6. Measure the residual activity in the catheter using a dose calibrator as previously described. 7. If mice are to be recovered ensure this is done in a warm environment (e.g., in a box with a heated pad underneath or containing a glove filled with warm water) to ease recovery. If planning to euthanize the mice, place the mice into an induction chamber containing isoflurane so that they remain anaesthetized prior to euthanasia via perfusion. 8. To reconstruct the data, open the post-processing managing software (see Table of Materials), which will automatically reconstruct each scan using the histogram data that was generated from the lst file.
Brain Autoradiography
1. Prior to the experiment, erase the digital autoradiography film by exposing it to white light for 10-15 min and keep in a radioactivity-free area until use. 2. Prepare 0.5 mL dose syringes for each mouse containing approximately 1.0-1.5 mCi/37-56 MBq to ensure a dose adequate for autoradiography. 3. Measure the radioactivity in the dose syringe, using a dose calibrator, prior to injection to obtain an accurate reading of the activity. 4. Cannulate as previously described and inject mice immediately in an area suitable for radioactivity. 5. Remove the catheter after injection and measure the residual radioactivity. 6. Leave the mice in a heated induction chamber so that they remain anaesthetized prior to perfusion and euthanasia. Open the abdominal cavity and cut through the diaphragm to expose the heart. 2. Insert a butterfly catheter infusion needle into the left ventricle of the heart, and snip the right atrium and inferior vena cava. 3. Slowly perfuse with PBS (~20-30 mL) using a 20 mL syringe.
8. Carefully remove the brain from the skull using forceps and scissors. 9. Place the brain in a freezing mold filled with optimal cutting temperature (OCT) liquid, making sure the brain is level and centered within the mold, with the olfactory bulbs oriented towards the notches in the mold (to provide landmarks and orientation once the brain is removed from the mold). 10. Place mold on dry ice for 10 -15 min or until the OCT becomes opaque. 11. Immediately place each mold in the cryostat microtome set to -18 °C, and equilibrate for 10 min prior to mounting. 12. Peel away the freezing mold and mount the brain to the microtome platform using a small amount of fresh OCT as the "glue". 13. Leave mounted brain in the microtome to freeze for 2 min. 14. Slice through the brain until the stroke location is exposed (i.e., ROI). Use the MR image to locate the infarct within the brain of each animal.
For dMCAO, this should consistently be in the somatosensory cortex; however, the length of the stroke may vary slightly. 15. Section the region of the brain spanning the infarct, placing 20 µm-thick sections on glass microscope slides labeled with the appropriate mouse number. 16. Open the autoradiography cassette and line the bottom of the cassette with one sheet of Saran wrap. Arrange the slides section side up on top of the saran wrap in the cassette and take note of the position of each slide. Optionally, take a picture of the slide placement to assist with later analysis. 17. Gently place another layer of saran wrap on top (after waiting ~2 min following collection of last brain section -allowing it to dry and adhere to the slide) and carefully place the digital autoradiography film (white side facing down) on top of the slides. 18. Close the cassette tightly and leave in a -20 °C freezer, allowing the sections to decay on the film for an adequate exposure time (~5-10 halflives). 19. Scan the film after the exposure time using a phosphor imager to generate a digital image for subsequent analysis. Image analysis software was used to determine the tracer uptake in ipsilateral and contralateral regions of interest (ROIs) using manually drawn ROIs and a semiautomated 3D split-brain atlas approach. Automatic 3D PET/CT registration was carried out followed by manual registration of the brain MRI within the corresponding mouse skull defined in the CT image. The 3D ROI tool was used to manually draw ipsilateral (red) and contralateral (green) ROIs using the infarct on the MRI as a reference. For the split-brain approach, the 3D left/right-split mouse brain atlas was loaded and fitted within the skull as defined by the CT image. Brain ROIs used for quantification in this 3D mouse brain atlas included Left Cortex ]DPA-713 uptake in the ipsilateral cortex of mice that underwent DMCAO (n = 3) and a slight increase for sham (n = 3) operated mice, with DMCAO mice demonstrating significantly greater contrast in percentage injected dose between the infarct and contralateral side of the brain (%ID/g). (B) PET quantification (50-60 min summed) revealed significantly increased uptake in the ipsilateral ROI using the ROI approach and in the cortex (Ctx) using the split-brain atlas approach. No significant differences were found in the hippocampus (HC) or striatum (Str). Increased ipsilateral to contralateral ratios were seen using both analysis approaches but was only statistically significant in the Ctx using the brain atlas approach. * (p <0.05), *** (p <0. 
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Discussion
The presented protocol describes a method for the quantification of neuroinflammation in dMCAO and sham mice using [ 11 C]DPA-713-PET. TSPO-PET is the most widely investigated imaging biomarker for visualizing and measuring neuroinflammation in vivo to date. TSPO expression is upregulated on glia in the brain during inflammation permitting the non-invasive detection and quantification of neuroinflammation. Moreover, it is a highly translatable technique, making it a valuable tool in both clinical and pre-clinical research. This protocol and representative results highlight the suitability of using [ In this study, dMCAO surgery was carried out using 3-month-old C57BL/6 female mice. This model was chosen as it gives rise to a highly reproducible infarct restricted to the somatosensory cortex, providing a model of permanent focal ischemia with low variability compared to other models of stroke (e.g., middle cerebral arterial occlusion (MCAO) filament method) 14 . PET imaging of stroke models has the advantage of containing an internal reference region in the brain for each animal using ROIs within the contralateral hemisphere. Since there will be some inflammation that results from the surgery alone, it is important to include mice that underwent sham surgery in the study design, whereby craniotomy and manipulation of meninges without artery occlusion was performed. Craniotomy alone can result in disruption to the underlying neuronal tissue and introduction of pathogens leading to immune responses independent of stroke 20 . Some inflammation after sham surgery is therefore expected and should be assessed in parallel to dMCAO to exclude the possibility of signal due to surgery alone. To avoid including inflammation resulting from the surgery without stroke in dMCAO cohort analysis, MR imaging must be conducted to confirm successful stroke surgery and infarct development. MRI also provides a structural reference frame, which is essential to accurately draw the infarct and contralateral ROIs. Additionally, accurate image processing including image registration and ROI definition are necessary to ensure reliable quantification.
Additional limitations must be kept in mind when working with C-11 labeled radiotracers for PET and autoradiography studies. It is imperative to consider the short half-life (20.33 min) of C-11, with its use generally restricted to research institutes with on-site cyclotron access. Appropriate radioactivity transportation route, dose administration, and acquisition time-points must be determined in advance with a pre-prepared detailed plan of the workflow of the experiment so that the team can work quickly and efficiently. The design and set-up of this study has been outlined to accommodate imaging of 4 mice simultaneously to increase the data output obtainable when using a C-11 tracer. If possible, it is advisable to have all mice cannulated and in the middle of their CT scan by the time the C-11 tracer arrives at the imaging facility to ensure minimal radiotracer decay prior to injection. This step-by-step protocol is also best carried out by a team containing at least 3 researchers to allow for quick cannulation, dose measurement, tracer injection, PET scanning and brain sectioning prior to significant radioactive decay. It requires two people to conduct the initiation of the PET scan and injection of all 4 mice simultaneously. The reason for beginning the PET acquisition just prior to injection is to ensure the pharmacokinetics and dynamics of tracer distribution in blood and regions of interest are accurately and completely captured. Many steps may require vigorous training and practice to ensure smooth running of the experiment. In particular, this protocol is dependent on successful tail vein cannulation of C57BL/6 mice, which can be difficult due to dark hair present on their tails, and may become more challenging after stroke has occurred or if imaging the same mice at multiple time-points.
Another consideration for PET imaging includes careful recording of radiotracer dose and residual activity measurements, including the exact time of measurement. This is essential for accurate decay correction of the injected dose at the time of the scan and is used to obtain an accurate measurement of tracer uptake (i.e., % ID/g) for each ROI. It is imperative to know the exact amount of radioactivity that was present in each mouse at the time of scanning to ensure accurate image analysis. Therefore, it is advisable to synchronize the clocks on the scanner computer and dose calibrator to avoid error when using short-lived isotopes such as C-11.
Accurate PET image quantification can also be limited by the accuracy of the scanner and set-up. Hence to ensure accurate quantification of PET/CT images, it is important to carry out quality control checks for both the CT and PET components of the scanner. CT quality control checks include X-ray source conditioning, dark/light, and center off set calibrations. These calibrations measure and correct for system noise and must be performed prior to acquisition as recommended by the scanner manufacturer. Calibrations should also be performed for the PET scanner. This typically involves scanning a "standard/ PET phantom" scan, containing a known concentration of radioactivity. When preparing the standard, it is best to use the same radioisotope used in the study, a comparable dose to that administered to a single mouse in a volume similar to the body of a mouse, and the same acquisition parameters as animal imaging. A 20 mL syringe filled with radiotracer diluted in water is used for the standard in this protocol, with the subsequent PET imaging results used to calculate a correction factor based on the actual dose measured by the calibration detector. The correction ratio can be applied to the imaging data acquired in the experiment to ensure accurate quantification of tracer uptake in regions of interest in PET images. This accounts for the positron range of the radionuclide in addition to considering any background activity present on the day of scanning. As the dose calibrator is an integral part of the generation of this correction factor, it is imperative that this equipment is also calibrated regularly according to the manufacturer guidelines.
When conducting ex vivo autoradiography it is important to pick an optimal time-point for euthanasia after injection, to ensure high signal-tobackground in region(s) of interest. Thirty minutes post-injection was chosen for [ 11 C]DPA-713 autoradiography using data acquired during dynamic PET imaging -i.e., the in vivo dynamic TACs as a guide, while also considering the short half-life of C-11 and the time involved to section and expose the brain tissue after extraction. Considering this, [ 11 C]DPA-713 autoradiography must be performed on a separate cohort of mice to allow for injection of a higher [ 11 C]DPA-713 dose and a 30 minute time-point for perfusion and euthanasia under anesthesia. Performing a small in vivo PET pilot study with a 3-4 mice prior to conducting ex vivo autoradiography will be helpful for determining the optimal time point for autoradiography. An additional consideration for ex vivo autoradiography is whether to recover the mice after injection or keep them anesthetized until euthanasia. Keeping them anesthetized mimics the conditions of the scan and ensures the radiotracer distribution or excretion kinetics are not altered by recovery. Furthermore, this prevents additional stress on the mice by avoiding recovery and subsequent induction. Finally, a useful addition to the ex vivo protocol would be to assess the regional damage in the brain slices used for autoradiography via immunohistochemical staining (after radioactive decay) to generate a high-resolution image of infarct location and volume.
As there are limitations with the use of a C-11 based tracer, this protocol can easily be modified for use with a F-18 (half-life of 109.77 min) based TSPO tracer, which may be more applicable to locations without an on-site cyclotron. Additionally, this protocol describes the use of a 4-mouse imaging set-up. Although this high throughput method is optimal when using a C-11 tracer, this protocol may also be modified for those using single mouse imaging beds. Careful planning and consistent training in the techniques outlined in this protocol will lead to the generation of a wealth of data using [ 11 C]DPA-713, which can easily be applied to probe the role of neuroinflammation in disease manifestation and progression in other rodent models of neurological disorders. Moreover, this technique could be used to assess the in vivo response to immunomodulatory therapeutics targeted at microglia/macrophages.
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